- Home
- USGO vs FATE Comparison
USGO vs FATE Comparison
Compare USGO & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USGO | FATE |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | Canada | United States |
| Employees | 9 | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.0M | 139.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | USGO | FATE |
|---|---|---|
| Price | $11.15 | $1.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $30.75 | $4.10 |
| AVG Volume (30 Days) | 94.5K | ★ 1.5M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.42 | $0.66 |
| 52 Week High | $17.98 | $1.94 |
Technical Indicators
Market Signals| Indicator | USGO | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 35.90 |
| Support Level | $8.34 | $0.96 |
| Resistance Level | $11.20 | $1.16 |
| Average True Range (ATR) | 1.06 | 0.10 |
| MACD | -0.20 | -0.05 |
| Stochastic Oscillator | 2.46 | 0.00 |
Price Performance
Historical ComparisonAbout USGO U.S. GoldMining Inc.
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.